Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine

Highlights • V503-006 was a randomized safety and immunogenicity study in females 12–26 years of age. • V503-006 evaluated 9vHPV vaccine in those with previous qHPV vaccination. • 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients. • 9vHPV vaccine was immunogenic for HPV 31/...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2015-11, Vol.33 (48), p.6855-6864
Main Authors: Garland, Suzanne M, Cheung, Tak-Hong, McNeill, Shelly, Petersen, Lone Kjeld, Romaguera, Josefina, Vazquez-Narvaez, Jorge, Bautista, Oliver, Shields, Christine, Vuocolo, Scott, Luxembourg, Alain
Format: Article
Language:English
Subjects:
9-Valent
Adolescent
Adult
Allergy and Immunology
Antibodies, Viral - blood
Cervical cancer
Child
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - pathology
Female
Females
GARDASIL
HPV
Human papillomavirus
Humans
Immunization
Immunoassay
Immunogenicity
Injection
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - adverse effects
Papillomavirus Vaccines - immunology
Placebos - administration & dosage
Safety
Treatment Outcome
Vaccine
Vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • V503-006 was a randomized safety and immunogenicity study in females 12–26 years of age. • V503-006 evaluated 9vHPV vaccine in those with previous qHPV vaccination. • 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients. • 9vHPV vaccine was immunogenic for HPV 31/33/45/52/58 in prior qHPV vaccine recipients.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.08.059